Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 28, 2017; 23(24): 4354-4368
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4354
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4354
Figure 2 Naringenin prevents necrosis and cholestasis in CCl4-treated rats.
Alanine aminotransferase (ALT) (A); alkaline phosphatase (AP) (B) and γ-glutamyl transpeptidase (γ-GTP) (C) activities were determined in serum from control rats, carbon tetrachloride (CCl4)-treated rats, CCl4 plus naringenin rats (CCl4 + NAR), and rats administered with NAR alone (NAR). Values represent the mean of experiments performed in duplicate assay ± SE (n = 8). aP < 0.05 vs control group; bP < 0.05 vs CCl4 group.
- Citation: Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P. Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways. World J Gastroenterol 2017; 23(24): 4354-4368
- URL: https://www.wjgnet.com/1007-9327/full/v23/i24/4354.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i24.4354